4.3 Article

Tramadol/acetaminophen combination tablets for the treatment of osteoarthritis flare pain: A multicenter, outpatient, randomized, double-blind, placebo-controlled, parallel-group, add-on study

Journal

CLINICAL THERAPEUTICS
Volume 24, Issue 2, Pages 282-297

Publisher

ELSEVIER
DOI: 10.1016/S0149-2918(02)85024-X

Keywords

osteoarthritis; OA flare pain; tramadol; acetaminophen; NSAIDs; COX-2-selective inhibitors

Ask authors/readers for more resources

Background: In a flare of osteoarthritis (OA) pain, increasing the dose of standard anti- inflammatory or routine analgesic drugs may, not he practical because of an increased incidence of side effects. In patient,, achieving inadequate pain relief from traditional non-. steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase (COX)-2-selective inhibitors, it may be appropriate to add an analgesic aent with a different mechanism of action, thereby targeting multiple components of the pain pathway. Objective: The addition of tramadol/acetaminophen tablets to existing therapy was compared with the addition of placebo in the treatment of OA flare pain. Methods: This was a multicenter. outpatient, randomized. double-blind, placebo-controlled. parallel-group, add-on study. patients received 1 or 2 tramadol/acetaminophen (37.5 mg/325 mg) tablets QID or matching placebo for 10 days in addition to ongoing C NSAID or COX-2-selective inhibitor therapy. The primary outcome measures were average daily pain intensity and average daily pain relief scores from days 1 through 5. Results: Three hundred eight patients were randomized to tramadol/acetaminophen (n = 197) or placebo (n = 111) and were followed for up to 10 days. Patients had a mean (+/-SD) age of 60.1 +/- 9.87 years. and were predominantly female (71.8%) and white (87.7%). Their mean (+/-SD) pain visual analog score at baseline was 73.2 +/- 11.8 mm. and their mean pain intensity score was 2.4 +/- 0.5 (on a scale from 0 = none to 3 = severe). Average daily pain intensity and pain relief scores were significantly improved with tramadol/acetaminophen compared with placebo on the primary assessment of efficacy from days 1 through 5 (both, P < 0.001) and on the assessment of efficacy from days 1 through 10 (both, P < 0.001). Tramadol/acetaminophen was significantly superior to placebo on the patients' and physicians' overall assessments of medication (both, P < 0.001) and on 3 of 4 subscales (pain [P = 0.004], physical function [P = 0.013], and overall [P = 0.008]) of the Western Ontario and McMaster Universities Osteoarthritis Index Questionnaire. The most common treatment-emergent adverse events with tramadol/acetaminophen were nausea, vomiting, and dizziness. No serious adverse events were reported in the tramadol/acetaminophen group. Conclusion: In this study, addition of tramadol/acetaminophen to NSAID or COX-2-selective inhibitor therapy was well tolerated and effective in the treatment of OA flare pain.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available